

# Special Issue

## Latest Development in Pancreatic Cancer

### Message from the Guest Editor

Advancement in pancreatic cancer management has been dishearteningly slow. In the age of molecularly-targeted drugs and immunotherapy, the best treatment option for advanced and metastatic patients, which is the majority, remain combinations of cytotoxic drugs. For those fortunate enough to undergo curative pancreatectomy, cancer recurrence continues to be a real and significant concern. This Special Issue will discuss recent development in our understanding of the biology and genomic characteristics, early detection research, innovations in the treatment of localized disease and therapeutics targeting novel targets in pancreatic cancer.

---

### Guest Editor

Prof. Dr. Wen Wee Ma

Division of Medical Oncology, Mayo Clinic, 200 First Street SW  
Rochester, MN 55905, USA

---

### Deadline for manuscript submissions

closed (30 November 2017)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/9821](https://mdpi.com/si/9821)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)